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OPINION

Open Access

Points-to-consider on the return of results
in epigenetic research
Stephanie O. M. Dyke1,2*, Katie M. Saulnier1†, Charles Dupras1†, Amy P. Webster3, Karen Maschke4, Mark Rothstein5,
Reiner Siebert6, Jörn Walter7, Stephan Beck3, Tomi Pastinen8,9 and Yann Joly1

Abstract
As epigenetic studies become more common and lead to new insights into health and disease, the return of
individual epigenetic results to research participants, in particular in large-scale epigenomic studies, will be of
growing importance. Members of the International Human Epigenome Consortium (IHEC) Bioethics Workgroup
considered the potential ethical, legal, and social issues (ELSI) involved in returning epigenetic research results and
incidental findings in order to produce a set of ‘Points-to-consider’ (P-t-C) for the epigenetics research community.
These P-t-C draw on existing guidance on the return of genetic research results, while also integrating the IHEC
Bioethics Workgroup’s ELSI research on and discussion of the issues associated with epigenetic data as well as the
experience of a return of results pilot study by the Personal Genome Project UK (PGP-UK). Major challenges include
how to determine the clinical validity and actionability of epigenetic results, and considerations related to environmental
exposures and epigenetic marks, including circumstances warranting the sharing of results with family members and
third parties. Interdisciplinary collaboration and good public communication regarding epigenetic risk will be
important to advance the return of results framework for epigenetic science.
Keywords: Return of results, Incidental findings, Epigenetics, ELSI

Background
Epigenetics is a fast-growing field of research that is
shedding light on the ways in which interactions with
the environment lead to changes in gene expression [1].
Over the past 20 years, some of the most concerning diseases of our time, such as many types of cancer, metabolic disorders, and neurodegenerative diseases, have
been associated with the disruption of epigenetic programs [2–6]. Processes such as aging and personal exposure to stress and trauma have also been associated
with altered epigenetic programs [7].
As human epigenome mapping and epigenetic research continue to progress, with the potential to influence our understanding of environmental exposures,
community health, and the health of future generations
[8–10], determining which individual epigenetic research
* Correspondence: stephanie.dyke@mcgill.ca
†
Katie M. Saulnier and Charles Dupras contributed equally to this work.
1
Centre of Genomics and Policy, Faculty of Medicine, McGill University,
Montreal, Quebec H3A 0G1, Canada
2
Montreal Neurological Institute, Faculty of Medicine, McGill University,
Montreal, Quebec H3A 2B4, Canada
Full list of author information is available at the end of the article

results might be communicated to research participants
and how this communication should take place are of
growing importance. The return of research results and
incidental findings is a topic that has been explored at
great length, mostly in the fields of genetics and imaging
[11–14]. Although epigenetic research is still in its infancy,
it is expected to elucidate many aspects of human health.
Scientific and bioethics considerations already point to a
number of areas where the potential risks and challenges
of the return of research results might differ in type or
scale from those relating to genetic data [15–19], and researchers have called for further guidance on the subject
[17, 19]. These differences are likely to impact notions of
the clinical validity and actionability of epigenetic results,
privacy considerations, and assessment of the circumstances that warrant the sharing of results, both with the
research participants themselves and with other individuals who may be concerned (for example, those who have
had similar environmental exposures).
The International Human Epigenome Consortium
(IHEC) is an international consortium with the objective
of ‘providing free access to high-resolution reference
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human epigenome maps for normal and disease cell
types to the research community’ [20, 21]. The IHEC
Bioethics Workgroup, an interdisciplinary group of researchers in science, ethics, policy, and the law, therefore
formed a Subgroup to anticipate and consider the ethical, legal, and social issues (ELSI) raised by the return of
epigenetic research results. This Subgroup has produced
a set of points-to-consider (P-t-C) for the community,
which has been approved by the Bioethics Workgroup
and IHEC Executive Committee.

Points-to-consider
Building on the consensus that has emerged from the
genetics literature and international ethics guidance [22,
23], we recognized that: “The view is becoming more
common [ …] that clinically valid and actionable individual research results should be offered to participants”
(Box 1, P-t-C point 1). This is not meant to imply that
further results should not be returned under certain circumstances, but clinically valid and actionable individual
results, whether they are incidental findings or directly
related to the research study, represent a minimum
threshold for the type of results to be considered. Our
P-t-C also stress, however, that “researchers are not expected to actively search for this information (all clinically valid and actionable individual results) unless it
forms part of their standard research practice” (Box 1,
P-t-C point 1), as doing so would create an undue burden on researchers. Furthermore, the definitions of the
terms ‘clinically valid’ and ‘actionable’ are not yet as
well-established in the epigenetics field as they are in
genetics. Therefore, we identified a number of characteristics and considerations concerning epigenetic data that
could help researchers to determine which results
should be returned according to the two criteria of clinical validity and actionability.
Other, more procedural recommendations were derived
and adapted from guidelines and literature on the return
of genetic results. These included the well-established requirement that results be returned only when the participant has accepted to receive the results after having been
given the option of agreeing or declining to this through
an informed consent process [22, 24].
We also warn of the possibility that epigenetic information may not be protected under genetic nondiscrimination laws because these laws use language that is
specific to genetics and may not cover all epigenetic data.
For example, such laws refer to genetic characteristics that
are acquired before birth (in Germany [25]) or to ‘DNA’,
‘RNA’, or ‘genotypes’ (in the United States [26] and Canada
[27]) [28–31]. Given the uncertainty about whether genetic
non-discrimination laws apply to epigenetic data, some individuals may be reluctant to enroll in specific epigenetic
studies or to give broad consent to the use of their

Page 2 of 9

biospecimens in research that could result in analysis of
their epigenetic information. Thus, genetic nondiscrimination laws may need to be applied in a way that
includes epigenetic data, or new laws focusing specifically
on epigenetics may need to be enacted.
Finally, ethical issues related to the disclosure of incidental findings or the return of results will depend on
the age and cognitive capacity of the research participant, including the potential for prenatal epigenetic testing. For example, it may be preferable to offer certain
results, such as the risk of adult-onset conditions, to
children once they are able to consent to this themselves
[32]. Furthermore, it may not be appropriate for parents
or legally authorized representatives to refuse to receive
actionable results on behalf of children or incapable
adults [33]. Although this point is not specific to epigenetics, we adopt a point on the need to develop specific
policies for the contexts of research in pediatrics and research involving adults who have been deemed incapable
of giving informed consent (Box 1, P-t-C point 8). This
need is well-established in guidelines for the return of
genetic results [14, 34, 35].
Having grounded our P-t-C in current guidance in the
field of genetics, our overarching aim was to bring attention to the particular issues associated with epigenetic
research data: the challenges that lie ahead for determining clinical validity and actionability in epigenetics; considerations related to environmental exposures and
epigenetic marks, including their impact on the sharing
of results with others; and, finally, the importance of
good communication regarding epigenetic risk (Box 1,
P-t-C points 2–5).
Clinical validity of epigenetic research results

Definitive molecular diagnosis of imprinting disorders,
such as Beckwith–Wiedemann syndrome (which is mainly
caused by genetic or epigenetic defects in the chromosome 11p15.5 region), can sometimes be reached by analysis of epigenetic marks alone [36]. Even for this very rare
group of diseases, however, an underlying DNA sequence
change (mutation) is commonly required to return a clinical diagnosis. Given the current uncertainty regarding the
clinical significance and application of the vast majority of
epigenetic data, returning clinically valid, actionable results from epigenetic research studies would require a
careful process of scientific and clinical review, both
across the field and of individual study results. As more
systematic evidence of the epigenetic causes of disease is
only beginning to emerge from large-scale epigenome
projects [21, 37–41], the establishment of exhaustive criteria for assessing the clinical validity and actionability of
epigenetic data would be premature at this time. Therefore, we focused on framing in general terms how epigenetic evidence might eventually compare to genetic data,
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Box 1 IHEC Points-to-consider on the return of epigenetic research results*

1. The view is becoming more common in the scientific, bioethics, and policy literature and in ethical guidelines that clinically valid and
actionable individual research results should be offered to participants. However, it is agreed that researchers are not expected to
actively search for this information (all clinically valid and actionable individual results) unless it forms part of their standard research
practice.
2. In determining the clinical validity and actionability of epigenetic data and communicating epigenetic risk, the following points
should be considered:
a) How accurate are the data? Consider the study’s quality-control processes and replication of measurements in a clinically accredited diagnostic laboratory before returning research results. Also consider the origin or source of the epigenetic data, which may
be important for its interpretation, that is, the cell and tissue composition, and the age and sex (not gender) of the individual.
b) Epigenetic marks may be dynamic; how stable are the acquired data (are they ‘temporarily stable’)? The research result might
require multiple samples at different time points to determine its stability.
c) Epigenetic variants or marks have the potential to cause disease. Depending on supporting evidence, three types of variants can
be distinguished:
 Associated variants: variants supported by statistics only (for example, in an epigenome-wide association study).

 Inferred variants: variants supported by statistics and inferred functional evidence (for example, involvement
in a plausible mechanism that has been inferred from additional data).

 Causal variants: variants supported by statistics and for which disease-causality has been demonstrated (for example,
in conjunction with genetic variants or where genetic variants have been ruled out). Causal variants are candidates for
clinical validation as a first step towards actionability.
d) For clinically valid variants, what is the level of disease risk and severity?
e) Epigenetic variants or marks may be diagnostic or a ‘biomarker’ even if they are not causal.
f ) The possibility of treatment or prevention based on the research result, including the potential ‘reversibility’ of epigenetic risk
variants. ‘Actionability’ may also include the possibility of making life choices on the basis of the result.
3. Research results may include epigenetic marks from different kinds of exposures (for example, pollution or certain behaviors) that
fall short of disease-causality, yet which are of interest to participants (for example, enabling them to avoid further potentially harmful exposures).
4. As epigenetic data result from both heredity and environmental exposures, individuals who might benefit from receiving this
information through further disclosure could eventually include research participants’ non-biological relatives, neighbors, co-workers,
or others with shared exposures. Such disclosure should only be made with the participants’ and other individuals’ consent or in accordance with local laws and policies.
5. Public communication of the general results of epigenetic research may have an important, yet often neglected, impact on how
individuals interpret their individual epigenetic results. Few epigenomic research projects currently produce clinically valid and
actionable individual research results, but many are generating research findings that are of interest to the public and to the media.
Good public communication of epigenetic risk by researchers and science communication professionals should be encouraged.
Procedural points
6. An epigenomic project should have a policy on return of research results in place, which is included in the ethics review for the
project, and is clearly explained to participants during the informed consent process prior to any sample collection. The policy
should include transparency about how results will be assessed for potential return of results. For fundamental research projects that
are not meant to generate clinically valid, actionable results, there should be a statement that results will not be returned, except in
the exceptional circumstance where unforeseen findings arise that are clinically valid and actionable, and recontact and consent of
participants is feasible (for example, if data are not irreversibly de-identified).
7. The return of research results should occur with the free and informed consent of adult participants, in a way that respects their
autonomy, including their right to decline the information if they so choose (the ‘right not to know’).

Dyke et al. Genome Medicine

(2019) 11:31

Page 4 of 9

8. Specific policies should be established for pediatric research and for research involving adults who have been deemed incapable of
giving informed consent. For example, it may not be appropriate for parents or legally authorized representatives to refuse to
receive actionable results on behalf of children or incapable adults.
9. Elements to consider in setting up procedures for offering the return of results include:
a) the expiration of any duty to return results (for example, at the end of the research project);
b) the estimated cost of the process;
c) human resources that will be involved (for example, genetic counselors, family physicians, and others) and the respective roles
of researchers and physicians;
d) the necessity of establishing a convenient procedure to collect and update the contact details of participants and to re-identify
them if warranted;
e) the potential privacy and security risks of holding participant identities and contact information and ways to mitigate these risks;
f ) the approach that will be taken regarding the disclosure of results to family and other potentially exposed individuals
depending on laws and jurisdictions;
g) the possibility that epigenetic information may not be protected information under genetic information anti-discrimination laws
in a given jurisdiction, and the need to adapt procedures accordingly. Participants should be aware of any additional risks that this
issue presents at the time of the initial consent to sample collection.
*

Also available from the IHEC website [102]

drawing on the criteria and scoring systems that have
evolved over many years to assess the significance and
clinical interpretation of genetic variants [42–46]. This
entailed breaking down the assessment of epigenetic data
that could potentially be communicated to participants
into the following constituent areas:
1. The accuracy of the epigenetic data with respect to
both the technology used and the source material
(cell composition, sample purity).
2. The stability of the epigenetic data. Some epigenetic
marks are more dynamic than others, so multiple
measurements over time might be required to
determine their significance [47, 48].
3. The existing level of evidence that a variant or mark
may cause disease or is associated with disease, the
magnitude of such disease risk, and the nature of
the disease.
4. And finally, the possibility of treating or preventing
disease or epigenetic risk variants (for example, by
systemic or targeted epigenetic therapy, or through
epigenetic screening).
In addition, we proposed specific terminology to
conceptualize the typical levels of evidence that are
found in discussions of epigenetic risk and disease.
Disease-associated or disease-causing variants would
thus fall into one of the following groups:
1. Associated variants: variants supported by
statistics only (for example, in an epigenomewide association study (EWAS)).

2. Inferred variants: variants supported by statistics
and inferred functional evidence (for example,
involvement in a plausible mechanism that has
been inferred from additional data).
3. Causal variants: variants supported by statistics and
for which disease-causality has been demonstrated
(for example, in conjunction with genetic variants
or where genetic variants have been ruled out).
Causal variants are candidates for clinical validation
as a first step towards actionability.
We also point out that epigenetic variants or marks may
be diagnostic or useful as ‘biomarkers’ of disease, even if
they are not causal (Box 1, P-t-C point 2e). They may also
be found to confer protection against disease. We hope
that these categories will serve as a starting point for defining levels of evidence in different areas of epigenetics,
as has been done in evaluating the clinical validity of
gene–disease associations, for example, by the Clinical
Genome Resource (ClinGen) [46, 49]. ClinGen is an initiative to provide an authoritative central resource that defines the clinical relevance of genes and genetic variants
for use in precision medicine and research. Approaches
that are commonly used to demonstrate the causality of
epigenetic variants are genetic manipulation of the DNA
sequence underlying an epigenetic variant or of the enzymes that are responsible for the establishment or removal of the epigenetic variant, or targeted editing of the
epigenetic variant itself [50].
Although we acknowledge that epigenetic variants and
their clinical interpretation may differ considerably from
genetic variants, we aimed to achieve two goals with this
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preliminary framework. First, to place the epigenetic research result that a researcher may be considering communicating in the context of a thorough assessment of
its analytical, scientific and clinical validity. Second, to
frame the result in terms of its likely impact on participants, both in its relevance to participant health and its
broader significance. This is particularly complex because of evidence that epigenetic marks may be reversible [48] and may sometimes provide information about
an individual’s environmental exposures [51], including
information that might be related to their and to others’
behavior [52].
Actionability of epigenetic research results

We considered that ‘actionability’—the potential for action
based on the epigenetic data that are returned—should extend beyond strict definitions of clinical utility to include
health-related data more broadly. For example, epigenetic
data might indicate an environmental or community exposure, resulting in epigenetic risk variants that could be
avoided, such as acceleration of the accumulation of altered DNA methylation biomarkers of aging (the epigenetic clock) [53]. Actionability could therefore include
clinical actions to prevent or treat disease or epigenetic
risk variants, as well as non-clinical actions that could be
enabled by knowledge of the epigenetic data, such as
health-related life choices, including reproductive decisions (for example, changing diet or other behaviors that
might be involved in health-related epigenetic variation).
The scope of the data that may potentially be of interest
to participants is wide, and we certainly did not intend to
suggest returning all results in all circumstances. In particular, we include a point about considering the magnitude and nature of the disease risk in weighing the
significance of a result (Box 1, P-t-C point 2d). Current
policies for the return of genetic information suggest that
the ‘severity’ of the disease to which an individual would
be predisposed is likely to be important in deciding how
critical the return of a result may be [54]. Epigenetic reversibility may also strengthen the ethical argument in
favor of disclosing an epigenetic research result, as it may
allow for greater preventive or treatment opportunities.
On the other hand, it may also lead to data that are not a
definitive indication of an individual’s epigenetic disease
risk—hence our specific point about the stability of epigenetic data (Box 1, P-t-C point 2b).
Examples of behaviors and other so-called ‘lifestyle’ exposures with known epigenetic effects include nutrition,
smoking, and stress [55–58]. While their inference is not
yet unequivocal, at least quantitatively, especially for the
more intangible exposures such as exposure to stress, it is
possible that such individual research results could be of
interest to research participants. Research in this area, and
into other environmental exposures, is growing [59, 60].
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For example, the National Institute of Environmental
Health Sciences (NIEHS) Toxicant Exposures and Responses by Genomic and Epigenomic Regulators of Transcription (TaRGET) II Consortium recently reported its
plans to investigate the conservation of environmentally
induced epigenetic alterations across tissues following environmental exposures that have been associated with adverse health outcomes [61]. As exposure science has
moved from measuring chemicals in the environment to
biomonitoring of such exposures in the population, novel
models of community-driven return of results and broader
communication plans are emerging [62].
Individual epigenetic information may be of interest to
participants who simply wish to know about their own
health status or to influence community health decisions. However, such information also has potential implications that extend to the area of public policy, and
more specifically, to areas of environmental tort (where
injury occurs via toxic exposure) and reproductive tort
(where injury occurs either pre-conception or in utero)
[63, 64]. For example, evidence is emerging that toxicity
from exposure to certain chemical hazards is driven at
least in part by epigenetic mechanisms, and researchers
have expressed concerns that assisted reproductive technologies may cause epigenetic damage to embryos [28,
64, 65]. Both environmental and reproductive torts are
founded on responsibility for harmful exposure and involve proof of three elements: breach of duty, causation,
and injury [64, 66, 67]. Of these, the causal element presents a particular conundrum in environmental and reproductive tort because the scientific evidence is not always
sufficiently clear to establish a direct causal link between
the action entailed in the breach of duty and the harm suffered by the plaintiff [66, 68]. Although evidence of general
causation is often provided by epidemiological data, evidence of specific causation requires a more fine-grained understanding (most of the time not available) of the
biological mechanisms underlying such statistical associations between exposure and harm. By providing insights at
the molecular level into how significant health risks may be
acquired through different manners of exposure, epigenetic
research could fill the existing gap in establishing actionable
evidence of specific causality [67, 69].
Finally, a few studies of transgenerational epigenetic effects, mainly in mouse models, indicate that
environmental and behavioral epigenetic signatures
could be inherited [8–10, 52, 70–73]. This possibility, if confirmed, might add to the range of research
data that could potentially be of interest to individuals, but it may also raise particular privacy concerns because the data would not only expose the
environmental and behavioral information of the research participant, but also possibly that of their
parents and grandparents.
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Disclosure of participants’ epigenetic data to relatives
and third parties

Disclosing personal genetic information to biological relatives can sometimes benefit family members who share
similar genetic-risk profiles. Even though some patients
may be reluctant to disclose—for instance, to prevent
unnecessary anxiety for family members [74]—some ethicists have argued that there may sometimes be a moral
‘genetic responsibility’ to share medically relevant information with interested third parties [75, 76]. Nevertheless, this moral responsibility can conflict with the
obligation of physicians and researchers to protect patient confidentiality, and physicians may also be legally
required to inform a patient about the potential ‘consequences that his or her silence may have on the health
of family members’ [77]. In the United States, federal
health privacy regulations prohibit the nonconsensual
disclosure of health information except in circumstances
inapplicable here, such as disclosures to public health or
law enforcement officials [78]. The superior approach is
for health care providers to counsel, encourage, and support patients to disclose relevant genetic information to
their at-risk relatives [79].
Ethical and legal debates about the disclosure of genetic
information to third parties have consistently focused on
the relevance of such information to the patient’s immediate family, that is, to ‘biological relatives’ who are likely to
share innate risks acquired through Mendelian inheritance
[80]. However, epigenetic research may soon force us to
expand the notion of biological relative—and thus the
range of people who could benefit from the disclosure of
epigenetic information—to include ‘individuals with
shared exposures’, that is, individuals who are likely to
share similar epigenetic risk factors [81]. This approach
will also benefit researchers who investigate DNA sequence mutations and other changes that are induced by
environmental exposures [82].
Consider the following hypothetical scenario: numerous studies have shown that a pesticide causes specific
epigenetic changes and phenotypes at the population
level. An investigator finds out that one of the research
participants in their study, who has worked as a farmer
all their life, has these epigenetic marks of exposure to
the pesticide. Therefore, the exposure occurred in all
likelihood at the workplace. Such a research result could
carry a number of direct clinical implications for different ‘categories’ of individuals other than the participant,
such as: 1) the farmer’s family (including non-genetically
related family members such as adopted children) living
near the contaminated site, as well as neighbors, as this
information could influence decisions surrounding
re-location away from the harmful exposure; 2) employees on the farm who may also be at risk of epigenetic effects resulting from frequent exposure to the
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pesticide; and 3) these individuals’ future children, if
there were a risk of possible transgenerational effects.
Example of returning epigenetic results: Personal Genome
Project UK

The Personal Genome Project UK (PGP-UK) [83] conducted a small pilot trial in 2016 to gain experience and
a first insight into any issues associated with reporting
incidental epigenetic findings to study participants.
Using open consent and open access data sharing protocols [84], PGP-UK recruited ten volunteers who agreed
to receive incidental epigenetic findings from the analysis of their DNA methylomes in addition to their
standard genome reports. Three categories of findings
were reported (sex, age, and smoking), for which the
analysis was judged to be sufficiently mature based on
independent validation and replication. The methylome
reports [85] were based on the analysis of around
450,000 genome-wide CpG sites in two specimens
(blood and saliva) from each participant [86].
In this small initial trial, there was high participant interest in, and acceptance of, receiving incidental epigenetic
findings, as assessed through discussion groups and
follow-up with volunteers, particularly the results associated with environmental exposures [86]. This supports
our view that results other than clinically actionable results are potentially of great interest to research participants. It also provides limited evidence that participants
could also be comfortable with receiving results of uncertain clinical significance, although the level of support provided for the return of results communication process in
this trial may not be as feasible for studies involving much
larger groups of research participants. Although we expect
good communication practices to improve participant understanding of individual results and encourage such efforts, we would not assume that personal preferences
regarding the receipt of results would necessarily differ in
the absence of such support. Indeed, social science studies
have shown that the vast majority of participants in genetics research and biobanking initiatives wish to receive individual results [87–95]. Furthermore, a large multi-study
survey found that providing a choice of different consent
and data sharing models did not have a significant impact
on willingness to participate in a biobank [96].

Conclusions and future directions
With these P-t-C, we aimed to draw attention to the
ELSI associated with the return of epigenetic research
results and we have outlined both the norms that have
emerged for genetic research results that are relevant
and new issues to consider for epigenetic research.
Much remains to be determined before we can arrive
at detailed guidance for the return of specific epigenetic
results, such as the recommendations that have been
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produced for clinical genome sequencing in the USA
[97, 98]. This will involve considerable research efforts
to better understand fundamental epigenetic and epigenomic processes and their relationship to disease, as well
as studies of the clinical validity and actionability of epigenetic data. We believe, however, that discussions about
the strength of epigenetic findings and their implications
for health and disease must begin now, while our understanding of the role of epigenetics is growing. Although
we found it useful to build on ELSI guidance from the
field of genetics, epigenetic data raise important new
challenges that may eventually lead to a very different
framework for the return of results.
Furthermore, as epigenetics is attracting much scientific interest and investment, its health implications and
potential to revolutionize the ‘nature versus nurture’ debate have also caught the imagination of the public [99–
101]. We focused here on the return of individual research results to participants, but the issues of the
broader communication and public understanding of
epigenetics should not be left out of the discussion.
These issues will, in all likelihood, frame both participants’ eventual understanding of any individual research
results and the broader societal debate on the implications of epigenetic science. Enhanced approaches for
communication with research participants, such as the
development of online ‘research portals’ to access and
discuss research findings, could provide the public with
greater opportunities for interaction with research studies and their results. With these P-t-C, we hope to
stimulate innovative, interdisciplinary public conversations about epigenetics and the implications of this science for individuals, families, and societies.
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